A post hoc analysis of the PATHWAY randomized clinical trial (RCT) showed that tezepelumab is effective in reducing exacerbation rates regardless of baseline serum TSLP concentration in patients with severe, uncontrolled asthma (54). The gene discussed is TSLP; the disease is asthma.